Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

NCT02387983 | Completed Phase 1 Results

• 1 other identifier: 5592-117
• Study Type: interventional
• Target: 65
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of oral posaconazole tablets in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study.

Conditions

Fungal Infection

Outcome Measures

Primary Outcomes (9)

• Steady-state Average Concentration (ssCavg) of Posaconazole on Day 8

  The ssCavg was calculated in order to determine the percentage of participants achieving the pharmacokinetic (PK) target of ssCavg \>500 ng/mL on Day 8 when plasma drug levels had reached steady state.

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

• Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of Posaconazole on Day 8

  The ssAUC0-24hr was calculated to determine the mean plasma drug concentration in the Intensive and Sparse PK subgroup from immediately after dosing to 24 hours post-dose on Day 8. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation \[CV\]), where CV is calculated as (100 x standard deviation/arithmetic mean).

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

• Steady-state Maximum Concentration (ssCmax) of Posaconazole on Day 8

  The ssCmax was calculated in order to determine the maximum post-dose plasma drug concentration in the Intensive and Sparse PK subgroup on Day 8. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation \[CV\]), where CV is calculated as (100 x standard deviation/arithmetic mean).

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

• Steady-state Minimum Concentration (ssCmin) of Posaconazole on Day 8

  The ssCmin was calculated in order to determine the lowest measurable drug concentration in the Intensive and Sparse PK subgroup up to 24 hours post-dose on Day 8. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation \[CV\]), where CV is calculated as (100 x standard deviation/arithmetic mean).

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

• Time to Steady-state Maximum Concentration (ssTmax) of Posaconazole on Day 8

  The ssTmax was calculated in order to determine the amount of time required to reach ssCmax in the Intensive and Sparse PK subgroup on Day 8.

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 8

• AUC0-24hr of Posaconazole on Day 1

  The AUC0-24hr was calculated to determine the mean plasma drug concentration from immediately after dosing to 24 hours post-dose in the Immediate and Sparse PK subgroup on Day 1. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation \[CV\]), where CV is calculated as (100 x standard deviation/arithmetic mean).

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

• Cmax of Posaconazole on Day 1

  The Cmax was calculated to determine the maximum plasma drug concentration up to 24 hours post-dose in the Immediate and Sparse PK subgroup on Day 1. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation \[CV\]), where CV is calculated as (100 x standard deviation/arithmetic mean).

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

• Cmin of Posaconazole on Day 1

  The Cmin was calculated in order to determine the lowest measurable drug concentration from immediately after dosing to 24 hours post-dose in the Immediate and Sparse PK subgroup on Day 1. Results data are presented as the arithmetic mean (% arithmetic coefficient of variation \[CV\]), where CV is calculated as (100 x standard deviation/arithmetic mean).

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

• Tmax of Posaconazole on Day 1

  The Tmax was calculated in order to determine the time required to reach Cmax in the Immediate and Sparse PK subgroup on Day 1.

  Pre-dose and 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1

Study Arms (1)

Posaconazole

EXPERIMENTAL

Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28

Drug: Posaconazole

Interventions

Posaconazole DRUG

Posaconazole 300 mg solid oral tablet

Also known as: MK-5592

Posaconazole

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Chinese participant
• Female of reproductive potential with a serum hCG level consistent with a nongravid state and agree to use 2 acceptable methods of birth control throughout the study
• Body Mass Index (BMI) \>=15 and \<=30 kg/m\^2
• Anticipated or documented prolonged neutropenia and likely to last for at least 7 days due to: a) standard intensive chemotherapy, anthracycline-based or other accepted regimen (excluding any investigational agent) for a new diagnosis of acute myelogenous leukemia (AML); b)chemotherapy for AML in first relapse; or c) therapy for myelodysplastic syndromes in transformation to AML or other diagnoses of secondary AML (therapy related, antecedent hematological disorders) or chronic myelogenous leukemia in blast crisis
• Free from any clinically significant disease other than the primary hematologic disease that would interfere with administration of study medication or study evaluations

You may not qualify if:

• Pregnant, intends to become pregnant during the study, or has been nursing
• Mentally or legally incapacitated, has significant emotional problems, or has clinically significant psychiatric disorder over the last 5 years
• Received systemic antifungal therapy (oral, intravenous, or inhaled) within 30 days of study enrollment for reasons other than antifungal prophylaxis
• Known or suspected invasive or systemic fungal infection
• Taken posaconazole within 10 days prior to study enrollment
• Major surgery, donated or lost 1 unit of blood, or participated in another investigational study within 4 weeks prior to the study
• Type 1 hypersensitivity or idiosyncratic reactions to azole agents
• Significant multiple or severe allergies, or has had an anaphylactic reaction or significant intolerability to drugs or food
• Moderate or severe liver dysfunction
• Chronic active hepatitis, cirrhosis, Hepatocellular Carcinoma (HCC), or other hepatic disease caused by a virus
• Previous electrocardiogram with a prolonged QTc interval
• Prior enrollment in this study or other posaconazole studies within 90 days of study entry
• Eastern Cooperative Oncology Group (ECOG) performance status was \>2 prior to induction chemotherapy for the underlying disease
• Known or suspected Gilbert's disease

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Publications (1)

• Liu K, Wu D, Li J, Chen H, Ning H, Zhao T, Dai H, Chen L, Mangin E, Winchell GA, Waskin H, Jiang J, Qiu Y, Zhao XM. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection. Adv Ther. 2020 May;37(5):2493-2506. doi: 10.1007/s12325-020-01341-x. Epub 2020 Apr 22.

  PMID: 32319040 DERIVED

MeSH Terms

Conditions

Mycoses

Interventions

posaconazole

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2015
• First Posted: March 13, 2015
• Study Start: May 6, 2015
• Primary Completion: May 2, 2016
• Study Completion: May 2, 2016
• Last Updated: October 9, 2018
• Results First Posted: July 14, 2017

Record last verified: 2018-09

Data Sharing

• IPD Sharing: Will share